PIM1 and breast cancer: Although overactivation of HER family was observed in many cancers, especially in breast cancer, ovarian cancer, and non-small cell lung cancer, and correlates with poor prognosis and drug resistance (Wang, 2017), it remains unclear whether Pim1 plays a role in the regulations of HER family expression and TKI resistance and functions a potential therapeutic target in breast cancer.